Evidence of MS-275 biologic effect
| Patient no. . | Dose level . | Type of response . | No. of cycles . |
|---|---|---|---|
| 2 | 4 mg/m2 × 2/4 wk | Bone marrow PR (>50% → 12% blasts, cycle 1) | 4 |
| Differentiation in myeloid lineage (ANC 504/μL → ANCmax 1410/μL, cycle 1) | |||
| 3 | 4 mg/m2 × 2/4 wk | Stable disease (bone marrow >20% → 11% blasts, cycle 1) | 2 |
| 5 | 4 mg/m2 × 2/4 wk (cycle 1); | Stable disease | 3 |
| 6 mg/m2 × 2/4 wk (cycle 2 and 3) | |||
| 11 | 8 mg/m2 × 2/4 wk | Decreased transfusion requirements | 1 |
| 14 | 8 mg/m2 × 4/6 wk | Resolution of bone pain | 1 |
| 15 | 8 mg/m2 × 4/6 wk | Bone marrow PR (35% → 14% blasts, cycle 1) | 1.75 |
| Differentiation in myeloid lineage (ANC 288/μL → ANCmax 2052/μL, cycle 1; ANCmax 5546/μL, cycle 2) | |||
| 18 | 8 mg/m2 × 4/6 wk | Differentiation in myeloid lineage (ANC 124/μL → ANCmax 680/μL, cycle 1) | 1.25 |
| 20 | 8 mg/m2 × 4/6 wk | Decreased transfusion requirements | 1 |
| 24 | 8 mg/m2 × 4/6 wk | Bone marrow PR (30% → 20% blasts, cycle 1) | 4.75 |
| Differentiation in myeloid lineage (ANC 520/μL → ANCmax 3637/μL, cycle 1; ANCmax 4456/μL, cycle 3) | |||
| 27 | 8 mg/m2 × 4/6 wk | Stable disease (peripheral blood 21% → 0% blasts, cycles 1 to 3; Bone marrow 68% → 34% blasts, cycle 1, 67% blast, cycle 4, 87% blasts, cycle 5) | 5 |
| 33 | 10 mg/m2 × 4/6 wk | Resolution of extramedullary chloroma | 2 |
| 34 | 10 mg/m2 × 4/6 wk | Bone marrow CR (54% → 3% blasts, cycle 1) | 2 |
| Differentiation in myeloid lineage (ANC 103/μL → ANCmax 854/μL, cycle 1; ANCmax 2929/μL, cycle 2) |
| Patient no. . | Dose level . | Type of response . | No. of cycles . |
|---|---|---|---|
| 2 | 4 mg/m2 × 2/4 wk | Bone marrow PR (>50% → 12% blasts, cycle 1) | 4 |
| Differentiation in myeloid lineage (ANC 504/μL → ANCmax 1410/μL, cycle 1) | |||
| 3 | 4 mg/m2 × 2/4 wk | Stable disease (bone marrow >20% → 11% blasts, cycle 1) | 2 |
| 5 | 4 mg/m2 × 2/4 wk (cycle 1); | Stable disease | 3 |
| 6 mg/m2 × 2/4 wk (cycle 2 and 3) | |||
| 11 | 8 mg/m2 × 2/4 wk | Decreased transfusion requirements | 1 |
| 14 | 8 mg/m2 × 4/6 wk | Resolution of bone pain | 1 |
| 15 | 8 mg/m2 × 4/6 wk | Bone marrow PR (35% → 14% blasts, cycle 1) | 1.75 |
| Differentiation in myeloid lineage (ANC 288/μL → ANCmax 2052/μL, cycle 1; ANCmax 5546/μL, cycle 2) | |||
| 18 | 8 mg/m2 × 4/6 wk | Differentiation in myeloid lineage (ANC 124/μL → ANCmax 680/μL, cycle 1) | 1.25 |
| 20 | 8 mg/m2 × 4/6 wk | Decreased transfusion requirements | 1 |
| 24 | 8 mg/m2 × 4/6 wk | Bone marrow PR (30% → 20% blasts, cycle 1) | 4.75 |
| Differentiation in myeloid lineage (ANC 520/μL → ANCmax 3637/μL, cycle 1; ANCmax 4456/μL, cycle 3) | |||
| 27 | 8 mg/m2 × 4/6 wk | Stable disease (peripheral blood 21% → 0% blasts, cycles 1 to 3; Bone marrow 68% → 34% blasts, cycle 1, 67% blast, cycle 4, 87% blasts, cycle 5) | 5 |
| 33 | 10 mg/m2 × 4/6 wk | Resolution of extramedullary chloroma | 2 |
| 34 | 10 mg/m2 × 4/6 wk | Bone marrow CR (54% → 3% blasts, cycle 1) | 2 |
| Differentiation in myeloid lineage (ANC 103/μL → ANCmax 854/μL, cycle 1; ANCmax 2929/μL, cycle 2) |